VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
VolitionRx (NYSE AMERICAN: VNRX) will host its Third Quarter 2025 earnings and business update conference call on Friday, November 14, 2025 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Central European Time).
The call will be hosted by Louise Batchelor, Group Chief Marketing & Communications Officer, with Cameron Reynolds, President and Group CEO; Terig Hughes, Group CFO; and Dr. Jake Micallef, Chief Scientific Officer, discussing Q3 2025 financial and operating results and upcoming milestones.
Dial-in numbers, Conference ID 13757129, a live audio webcast link, and a telephone replay available through November 28, 2025 are provided for investors and analysts.
VolitionRx (NYSE AMERICAN: VNRX) ospiterà la sua conferenza sui risultati e sull'aggiornamento aziendale del terzo trimestre 2025 venerdì 14 novembre 2025 alle 8:30 a.m. ora orientale degli Stati Uniti (14:30 CET).
La chiamata sarà moderata da Louise Batchelor, Group Chief Marketing & Communications Officer, insieme a Cameron Reynolds, Presidente e Amministratore Delegato del Gruppo; Terig Hughes, Group CFO; e il Dr. Jake Micallef, Chief Scientific Officer, che discuteranno i risultati finanziari e operativi del Q3 2025 e le tappe future.
Per gli investitori e gli analisti sono disponibili numeri di accesso, l'ID conferenza 13757129, un link per lo streaming audio in diretta e una riproduzione telefonica attiva fino al 28 novembre 2025.
VolitionRx (NYSE AMERICAN: VNRX) organizará su conferencia de resultados y actualización comercial del tercer trimestre de 2025 el viernes 14 de noviembre de 2025 a las 8:30 a.m. hora del Este de EE. UU. (14:30 CET).
La llamada estará a cargo de Louise Batchelor, Group Chief Marketing & Communications Officer, junto con Cameron Reynolds, Presidente y Group CEO; Terig Hughes, Group CFO; y el Dr. Jake Micallef, Chief Scientific Officer, para discutir los resultados financieros y operativos del Q3 2025 y los hitos por venir.
Para los inversores y analistas, se proporcionarán números de marcación, el ID de la conferencia 13757129, un enlace de webcast de audio en directo y una grabación telefónica disponible hasta el 28 de noviembre de 2025.
VolitionRx (NYSE AMERICAN: VNRX)는 2025년 3분기 실적 및 비즈니스 업데이트 컨퍼런스콜을 2025년 11월 14일 금요일 미국 동부 표준시 기준 오전 8시 30분 (중부 유럽 표준시 14:30)에 개최합니다.
호스트는 Louise Batchelor, Group Chief Marketing & Communications Officer이며 Cameron Reynolds, 그룹 회장 겸 CEO; Terig Hughes, Group CFO; Dr. Jake Micallef, Chief Scientific Officer가 함께 2025년 3분기 재무·운영 실적 및 향후 이정표를 논의합니다.
투자자와 분석가를 위한 전화 접속 번호, 회의 ID 13757129, 라이브 오디오 생방송 링크 및 2025년 11월 28일까지 이용 가능한 전화 리플레이가 제공됩니다.
VolitionRx (NYSE AMERICAN: VNRX) organisera son appel-conférence sur les résultats et la mise à jour commerciale du troisième trimestre 2025 le vendredi 14 novembre 2025 à 8 h 30, heure de référence de l’Est des États-Unis (14 h 30, heure d’Europe centrale).
L’appel sera animé par Louise Batchelor, Directrice Marketing & Communications du Groupe, avec Cameron Reynolds, Président et PDG du Groupe; Terig Hughes, Directeur financier du Groupe; et le Dr Jake Micallef, Directeur Scientifique, pour discuter des résultats financiers et opérationnels du T3 2025 et des jalons à venir.
Pour les investisseurs et analystes, des numéros d’accès, l’ID de la conférence 13757129, un lien de webcast audio en direct et une rediffusion téléphonique seront disponibles jusqu’au 28 novembre 2025.
VolitionRx (NYSE AMERICAN: VNRX) wird am Freitag, dem 14. November 2025, um 8:30 Uhr Eastern Time die Earnings- und Geschäfts-Updates-Konferenz für das dritte Quartal 2025 veranstalten (14:30 Uhr CET).
Die Sitzung wird von Louise Batchelor, Group Chief Marketing & Communications Officer, moderiert, gemeinsam mit Cameron Reynolds, Präsident und Group CEO; Terig Hughes, Group CFO; und Dr. Jake Micallef, Chief Scientific Officer, die die finanziellen und betrieblichen Ergebnisse des dritten Quartals 2025 sowie anstehende Meilensteine besprechen.
Dial-in-Nummern, die Conferencing-ID 13757129, ein Link zum Live-Audio-Webcast und eine telefonische Wiedergabe, die bis zum 28. November 2025 verfügbar ist, stehen Investoren und Analysten zur Verfügung.
VolitionRx (NYSE AMERICAN: VNRX) ستستضيف مكالمة مؤتمر حول الأرباح وتحديث الأعمال للربع الثالث 2025 يوم الجمعة 14 نوفمبر 2025 في الساعة 8:30 صباحًا بتوقيت شرق الولايات المتحدة (2:30 بعد الظهر بتوقيت وسط أوروبا).
وستنظم المكالمة من قبل ليز باتشيلور، كبيرة مسؤولي التسويق والاتصالات بالمجموعة، بمشاركة كاميرون رينولدز، الرئيس والمدير التنفيذي للمجموعة؛ تيريج هيوز، المدير المالي للمجموعة؛ والدكتور جاك ميكالف، المدير العلمي، لمناقشة نتائج الربع الثالث 2025 والإطار الزمني للمراحل القادمة.
أرقام الاتصال، ومعرّف المؤتمر 13757129، ورابط بث صوتي مباشر، وإعادة اتصالات هاتفية متاحة حتى 28 نوفمبر 2025 مخصصة للمستثمرين والمحللين.
- None.
- None.
Conference call to take place on Friday, November 14 at 8:30 a.m.
Event: VolitionRx Limited Third Quarter 2025 Earnings and Business Update Conference Call
Date: Friday, November 14, 2025
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13757129
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer and Dr. Jake Micallef, Chief Scientific Officer. The call will provide an update on important events that have taken place in the third quarter of 2025 and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until November 28, 2025. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-third-quarter-2025-earnings-conference-call-and-business-update-302610111.html
SOURCE VolitionRx Limited